| 000 | 01655 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517223744.0 | ||
| 264 | 0 | _c20191024 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1537-6591 | ||
| 024 | 7 |
_a10.1093/cid/ciy228 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFulcher, Jennifer A | |
| 245 | 0 | 0 |
_aEmergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir. _h[electronic resource] |
| 260 |
_bClinical infectious diseases : an official publication of the Infectious Diseases Society of America _c08 2018 |
||
| 300 |
_a791-794 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAntiretroviral Therapy, Highly Active |
| 650 | 0 | 4 | _aDrug Resistance, Viral |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV Integrase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 3-Ring _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIntegrases _xgenetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aOxazines |
| 650 | 0 | 4 | _aPiperazines |
| 650 | 0 | 4 | _aPyridones |
| 650 | 0 | 4 | _aSequence Analysis, DNA |
| 650 | 0 | 4 | _aTreatment Failure |
| 700 | 1 | _aDu, Yushen | |
| 700 | 1 | _aZhang, Tian-Hao | |
| 700 | 1 | _aSun, Ren | |
| 700 | 1 | _aLandovitz, Raphael J | |
| 773 | 0 |
_tClinical infectious diseases : an official publication of the Infectious Diseases Society of America _gvol. 67 _gno. 5 _gp. 791-794 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/cid/ciy228 _zAvailable from publisher's website |
| 999 |
_c28560534 _d28560534 |
||